Impact of Mitral Regurgitation on Coronary Haemodynamics and Instantaneous Effect of Transcatheter Mitral Valve Repair
Key facts
- Who runs it
- University Hospital, Geneva
- Where
- Switzerland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 1 person enrolled
- Started
- 8 Jan 2020
- Ended
- 31 Jan 2025
- Type of study
- Interventional
- Treatments tested
- Measure of hemodynamic indices in a stenosed coronary artery using a pressure wire
- Record updated
- 4 February 2025
- Why it stopped
- Slow enrolment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age ≥18 years
- Patients with significant degenerative or functional MR planned for TMVR with the percutaneous edge-to-edge mitral valve repair MitraClip system
- Patients with ≥ 1 coronary artery lesion with angiographically-documented ≥50% diameter stenosis,
- Patient willing and able to provide written informed consent
Who cannot take part
- Previous coronary artery bypass surgery
- Acute coronary syndrome with recent ST-elevation myocardial infarction <5 days prior to randomization, or ongoing non-ST elevation acute coronary syndrome with biomarkers (cardiac troponin) still rising
- Cardiogenic shock/hemodynamic instability at the time of intervention (heart rate<50 beats per minute, systolic blood pressure <90mmHg) and/or need for mechanical/pharmacologic hemodynamic support
- Significant contraindication to adenosine administration (e.g. heart block, severe asthma)
- Presence of ≥1 coronary total occlusion(s)
- Documented non-viable myocardium in the area of the corresponding coronary artery being studied
- Severe left ventricular systolic dysfunction (<30%)
- Systolic pulmonary artery pressure > 70 mmHg on baseline echocardiography
- Extremely calcified or tortuous vessels precluding invasive coronary physiology measurement
- Hypertrophic cardiomyopathy, restrictive pericarditis, constrictive pericarditis, infiltrative cardiomyopathy
- Participation or planned participation in another clinical trial, except for observational registries
- Patients unable or unwilling to provide written informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In the present study, the investigators aim to use the in-vivo Transcatheter Mitral Valve Repair (TMVR) model to determine how Mitral Regurgitation (MR) affects coronary hemodynamics in patients affected with severe MR and concomittant angiographically-documented coronary artery disease. The investigators will also provide unique physiologic data on the acute effect of TMVR using the MitraClip system on coronary microcirculation in patients with severe MR.
The group in the trial
- Transcatheter Mitral Valve Repair armTreatment being tested
Patients with severe Mitral Insufficiency with concomitant intermediate coronary artery stenosis undergoing Transcatheter Mitral Valve Repair using the percutaneous edge-to-edge MitraClip system
Treatment: Measure of hemodynamic indices in a stenosed coronary artery using a pressure wire
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Impact of Mitral Valve Regurgitation on Coronary Haemodynamics and the Instantaneous Effect of Transcatheter Mitral Valve Repair: The MitraFLOW Study
- Record updated
- 4 February 2025